triethylenephosphoramide has been researched along with Metastase in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Di, L; Lyerly, HK; Ren, J; Shao, H; Song, G; Song, Q; Wang, X; Yang, H; Yu, J; Zhou, X; Zhu, X | 1 |
| Aisner, J; Cohen, BE; Egorin, MJ; Gutierrez, PL; Kohlhepp, EA | 1 |
2 other study(ies) available for triethylenephosphoramide and Metastase
| Article | Year |
|---|---|
Transformation of alkylating regimen of thiotepa into tepa determines the disease progression through GSTP1 gene polymorphism for metastatic breast cancer patients receiving thiotepa containing salvage chemotherapy.
Topics: Aged; Antineoplastic Agents, Alkylating; Biotransformation; Breast Neoplasms; Chi-Square Distribution; China; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP3A; Disease Progression; Disease-Free Survival; Female; Genotype; Glutathione S-Transferase pi; Humans; Logistic Models; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Odds Ratio; Patient Selection; Pharmacogenetics; Phenotype; Polymorphism, Single Nucleotide; Retrospective Studies; Risk Factors; Salvage Therapy; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Thiotepa; Time Factors; Treatment Outcome; Triethylenephosphoramide | 2015 |
Human plasma pharmacokinetics and urinary excretion of thiotepa and its metabolites.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chromatography, Gas; Half-Life; Humans; Hydrogen-Ion Concentration; Kinetics; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Thiotepa; Triethylenephosphoramide | 1986 |